Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors.

[1]  Germana Barata,et al.  Third Tofo Advanced Study Week on Emerging and Re-emerging Viruses, 2018 , 2018, Antiviral Research.

[2]  C. Solas,et al.  High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. , 2002, Journal of acquired immune deficiency syndromes.

[3]  Johan Gabrielsson,et al.  Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .

[4]  S. Khoo,et al.  Development of Enzymatic Assays for Quantification of Intracellular Lamivudine and Carbovir Triphosphate Levels in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients , 2002, Antimicrobial Agents and Chemotherapy.

[5]  D. Breilh,et al.  Pharmacokinetics and Resistance Mutations Affect Virologic Response to Ritonavir/Saquinavir-Containing Regimens , 2001, Therapeutic drug monitoring.

[6]  C. Fletcher,et al.  Clinical pharmacologic considerations for HIV-1 protease inhibitors , 2001, Current infectious disease reports.

[7]  M. Hirsch,et al.  Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.

[8]  Peter L. Anderson,et al.  Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir , 2001, Antimicrobial Agents and Chemotherapy.

[9]  Jeff D. Moore,et al.  Simultaneous quantitation of the 5′-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry , 2000, Journal of the American Society for Mass Spectrometry.

[10]  D. Katzenstein,et al.  Competing drug–drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884 , 2000, AIDS.

[11]  O. Rosario,et al.  Simultaneous Quantitation of Intracellular Zidovudine and Lamivudine Triphosphates in Human Immunodeficiency Virus-Infected Individuals , 2000, Antimicrobial Agents and Chemotherapy.

[12]  D. Haas,et al.  Steady‐state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection , 2000, Clinical pharmacology and therapeutics.

[13]  J. Mellors,et al.  3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine , 2000, Annals of Internal Medicine.

[14]  D. Cooper,et al.  Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy , 2000, AIDS.

[15]  A S Perelson,et al.  Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.

[16]  A. Fauci,et al.  Benchmarks for antiretroviral therapy. , 2000, The Journal of clinical investigation.

[17]  Peter L. Bonate,et al.  Clinical Trial Simulation in Drug Development , 2000, Pharmaceutical Research.

[18]  R. Schinazi,et al.  Cellular Pharmacology of the D- and L-Enantiomers of β-5-o-Carboranyl-2′-deoxyuridine , 2000, Nucleosides, nucleotides & nucleic acids.

[19]  M. Cloyd,et al.  How does HIV cause AIDS? The homing theory. , 2000, Molecular medicine today.

[20]  A. Perelson,et al.  A model of HIV-1 pathogenesis that includes an intracellular delay. , 2000, Mathematical biosciences.

[21]  A S Perelson,et al.  Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Beijnen,et al.  The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. , 1999, AIDS.

[23]  M. Hirsch,et al.  A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. , 1999, The Journal of infectious diseases.

[24]  Anthony S. Fauci,et al.  Both Memory and CD45RA+/CD62L+ Naive CD4+ T Cells Are Infected in Human Immunodeficiency Virus Type 1-Infected Individuals , 1999, Journal of Virology.

[25]  M. Parniak,et al.  HIV resistance to zidovudine: the role of pyrophosphorolysis. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  W. Heneine,et al.  A Rapid Non-Culture-Based Assay for Clinical Monitoring of Phenotypic Resistance of Human Immunodeficiency Virus Type 1 to Lamivudine (3TC) , 1999, Antimicrobial Agents and Chemotherapy.

[27]  C. Solas,et al.  Intracellular Nucleotides of (−)-2′,3′-Deoxy-3′-Thiacytidine in Peripheral Blood Mononuclear Cells of a Patient Infected with Human Immunodeficiency Virus , 1998, Antimicrobial Agents and Chemotherapy.

[28]  M. Feinberg,et al.  Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Vol. 47/No. RR-5. , 1998 .

[29]  J. Montaner,et al.  The effects of lamivudine treatment on HIV‐1 disease progression are highly correlated with plasma HIV‐1 RNA and CD4 cell count , 1998, AIDS.

[30]  I. Schlichting,et al.  The bottleneck in AZT activation , 1997, Nature Medicine.

[31]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Lancet,et al.  Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial , 1997, The Lancet.

[33]  M. Zupancic,et al.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. , 1997, Science.

[34]  E. Garvey,et al.  Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89 , 1997, Antimicrobial agents and chemotherapy.

[35]  B. Hirschel,et al.  Antiretroviral therapy: a guide to the most important trials. , 1997, Swiss medical weekly.

[36]  M A Nowak,et al.  Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. , 1997, Journal of theoretical biology.

[37]  A. Breckenridge,et al.  The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites , 1996, AIDS.

[38]  C. Katlama,et al.  Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients : A randomized controlled comparison with zidovudine monotherapy , 1996 .

[39]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[40]  D. Kuritzkes,et al.  Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .

[41]  M. Otto,et al.  In vitro susceptibility of clinical isolates of HIV‐1 to XM323, a non‐peptidyl HIV protease inhibitor , 1994, AIDS.

[42]  Robin A. Weiss,et al.  How does HIV cause AIDS , 1993 .

[43]  W. Parker,et al.  Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism , 1993, Antimicrobial Agents and Chemotherapy.

[44]  W. H. Miller,et al.  Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate. , 1990, The Journal of biological chemistry.

[45]  R. Siliciano,et al.  The challenge of viral reservoirs in HIV-1 infection. , 2002, Annual review of medicine.

[46]  R. Leavitt,et al.  Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3. , 2000, Revista do Instituto de Medicina Tropical de Sao Paulo.

[47]  Alan S. Perelson,et al.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.

[48]  R. Brack-Werner.  Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. , 1999, AIDS.

[49]  J. Sommadossi.  Pharmacological considerations in antiretroviral therapy. , 1998, Antiviral therapy.

[50]  B. Walker,et al.  Report of the NIH Panel To Define Principles of Therapy of HIV Infection* , 1998, Annals of Internal Medicine.

[51]  B. Sadler,et al.  In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. , 1996, Antiviral research.

[52]  D J Morris,et al.  Does HIV cause AIDS? , 1990, Journal of acquired immune deficiency syndromes.